

# Drug-Drug Interactions Between ADHD and Cardiometabolic Medications: a Pharmacovigilance Study

**First published:** 03/10/2025

**Last updated:** 03/10/2025

Study

Planned

## Administrative details

### EU PAS number

EUPAS1000000761

---

### Study ID

1000000761

---

### DARWIN EU® study

No

---

### Study countries

- ☐ Australia
  - ☐ Denmark
  - ☐ Sweden
  - ☐ United States
-

## Study description

Attention-deficit/hyperactivity disorder (ADHD) is increasingly recognized as a lifelong condition, with rising diagnoses and medication use among adults. ADHD medications, while effective, can influence cardiovascular function, and many patients are co-prescribed cardiometabolic treatments. This project investigates the safety of concurrent use of ADHD and cardiometabolic medications, given elevated cardiometabolic risks and overlapping pharmacological effects. We first screened for drug-drug interaction (DDI) signals using disproportionality analyses in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the European Medicines Agency's EudraVigilance database, and then estimated the prevalence of concurrent ADHD and cardiometabolic medication use with potential DDIs among ADHD medication users using population-based prescription databases from four countries.

---

## Study status

Planned

## Research institutions and networks

### Institutions

Department of Medical Epidemiology and  
Biostatistics, Karolinska Institutet

☐ Sweden

**First published:** 30/10/2024

**Last updated:** 30/10/2024

Institution

Educational Institution

ENCePP partner

## University of New South Wales (UNSW Sydney)

☐ Australia

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

Educational Institution

## Aarhus University

**First published:** 01/02/2024

**Last updated:** 01/02/2024

Institution

## SUNY Upstate Medical University

### Networks

## TIMESPAN

☐ Australia

☐ Denmark

☐ Germany

- ☐ Hong Kong
- ☐ Iceland
- ☐ Ireland
- ☐ Italy
- ☐ Netherlands
- ☐ Norway
- ☐ Spain
- ☐ Sweden
- ☐ United Kingdom
- ☐ United States

**First published:** 21/03/2025

**Last updated:** 21/03/2025

Network

## Contact details

### Study institution contact

Zheng Chang [zheng.chang@ki.se](mailto:zheng.chang@ki.se)

Study contact

[zheng.chang@ki.se](mailto:zheng.chang@ki.se)

### Primary lead investigator

Zheng Chang 0000-0002-8087-1417

Primary lead investigator

### ORCID number:

0000-0002-8087-1417

# Study timelines

## **Date when funding contract was signed**

Planned: 01/04/2024

---

## **Study start date**

Planned: 01/10/2025

---

## **Date of final study report**

Planned: 30/03/2026

# Sources of funding

- EU institutional research programme

## More details on funding

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 965381. This research reflects only the authors' view, and the European Commission is not responsible for any use that may be made of the information it contains.

# Study protocol

[Common analysis protocol\\_DDI between ADHD and cardiometabolic medications.pdf](#) (343.85 KB)

# Regulatory

**Was the study required by a regulatory body?**

No

---

**Is the study required by a Risk Management Plan (RMP)?**

Not applicable

## Methodological aspects

### Study type

#### Study type list

**Study topic:**

Human medicinal product

---

**Study type:**

Non-interventional study

---

**Scope of the study:**

Hypothesis generation (including signal detection)

Safety study (incl. comparative)

**Data collection methods:**

Secondary use of data

---

**Main study objective:**

First, we screened for drug-drug interaction (DDI) signals from the FAERS and the EudraVigilance database.

Second, we examined the prevalence of concurrent ADHD and cardiometabolic medication use with potential DDI among ADHD medication users in four

countries.

## Study Design

### **Non-interventional study design**

Case-control

## Study drug and medical condition

### **Medicinal product name, other**

ADHD medications including methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, atomoxetine and guanfacine.

## Population studied

### **Short description of the study population**

In the first step, we screened for drug–drug interaction (DDI) signals from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the European Medicines Agency’s EudraVigilance database.

In the second step, we examined the prevalence of concurrent ADHD and cardiometabolic medication use with potential DDIs among ADHD medication users in Australia (residents in the state of New South Wales, MedIntel Data Platform), Denmark and Sweden (linkage of national health registers), as well as the US (federated EHR from the TriNetX Research Network database).

---

### **Age groups**

- **Paediatric Population (< 18 years)**
  - Neonate

- Preterm newborn infants (0 – 27 days)
- Term newborn infants (0 – 27 days)
- Infants and toddlers (28 days – 23 months)
- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)
- **Adult and elderly population (≥18 years)**
  - Adults (18 to < 65 years)
    - Adults (18 to < 46 years)
    - Adults (46 to < 65 years)
  - Elderly (≥ 65 years)
    - Adults (65 to < 75 years)
    - Adults (75 to < 85 years)
    - Adults (85 years and over)

## Study design details

### Data analysis plan

We analyzed individual case safety reports (ICSRs) from two pharmacovigilance databases: FAERS (2004-2024) and EudraVigilance (2002-2024). Both systems collect post-marketing reports submitted by healthcare professionals, patients, and marketing authorization holders. The reference set comprised reports that included at least one ADHD medication during the study period. ADHD medication was defined using WHO ATC codes and included methylphenidate (N06BA04), amphetamine (N06BA01), dexamfetamine (N06BA02), and lisdexamfetamine (N06BA12), atomoxetine (N06BA09) and guanfacine (C02AC02). Cardiometabolic medications were defined as agents within ATC groups C (cardiovascular system), A10 (drugs used in diabetes), and B01 (antithrombotic agents). Serious outcomes were defined in FAERS as: death; life-threatening event; hospitalization (initial or prolonged); disability;



congenital anomaly; required intervention to prevent permanent impairment or damage; and other medically important condition. In EudraVigilance, serious outcomes included: death; life-threatening event; hospitalization (initial or prolonged); disability; congenital anomaly; and other medically important condition. Potential DDI signals were screened using three disproportionality methods—reporting odds ratio (ROR), proportional reporting ratio (PRR), and the Bayesian confidence propagation neural network (BCPNN) - computed independently in each database.

We applied a common, preregistered protocol to assess the real-world prevalence of the identified DDI pairs in four countries (Australia, Denmark, Sweden, and the United States). For each calendar year, we calculate the prevalence of concurrent use of ADHD and cardiometabolic medication associated with DDIs identified in the first step among ADHD medication users.

## Data management

### ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

## Data sources

### **Data source(s)**

Linkage of Swedish national registers for psychiatric research

**Data source(s), other**

TriNetX Research Network database

Medicines Intelligence (MedIntel) Data Platform, a linked data resource of Medicare-eligible people who are  $\geq 18$  years and residing in New South Wales (NSW), Australia.

---

**Data sources (types)**

[Administrative healthcare records \(e.g., claims\)](#)

## Use of a Common Data Model (CDM)

**CDM mapping**

No

## Data quality specifications

**Check conformance**

Yes

---

**Check completeness**

Yes

---

**Check stability**

Yes

---

**Check logical consistency**

Yes

---

## Data characterisation

**Data characterisation conducted**

Unknown